Compare AbCellera Biologics Inc (ABCL) vs SoFi Technologies Inc (SOFI) Price & Performance

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

SOFI stock trades at $18.02, down 0.55% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong Q2 2026 results, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75-$4.85 billion. The stock is trading below the consensus price target of $19.50, with analyst sentiment mixed but leaning positive.

The outlook for SOFI is supported by robust member growth and a diversified revenue stream, though risks include dependence on lending growth and potential interest rate sensitivity. The current valuation at a P/E of 36.69 and P/S of 5.6 reflects high growth expectations. Upside potential exists if execution continues, but investors should weigh the premium valuation against competitive and macroeconomic headwinds.